TCR2 Therapeutics Inc., a clinical-stage cell therapy company, is tackling cancer head-on with its groundbreaking T cell receptor (TCR) therapies. The company's lead product, gavo-cel, is a mono TCR Fusion Construct T cells (TRuC-T cells) engineered to target mesothelin-expressing solid tumors. This cutting-edge treatment is currently in Phase 1/2 clinical trial for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. TCR2 is also developing TC-510, a mesothelin-targeted TRuC-T cell that has successfully completed preclinical trials for solid tumor treatment. In addition, TC-520, a fratricide-resistant CD70 targeting TRuC-T cell, is in development to treat renal cell carcinoma and acute myeloid leukemia. Originally known as TCR2, Inc., the company took on its current name in November 2016. Headquartered in Cambridge, Massachusetts, TCR2 Therapeutics Inc. was incorporated in 2015 and has made substantial progress in the field of cancer research.